author-photo

Friedrich Graf Finckenstein

Bristol-Myers Squibb

27

Papers

335

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT246: A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

2020
Show All
- Source
- Cite
- Save
Citations (1)
A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)